30.04.2008 New quality stage - receiving certificates: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.As a result of positive Integrated Management System audit which took place on 15th and 16th. April 2008 Laboratory of Research and Development of Biotechnological Drugs has received the following certificates: ISO 9001, ISO 14001, ISO 18001/OHSAS 2007.
19.12.2007 Celon Pharma publishing results of preclinical studies using
siRNA in Cancer Biology and Therapy."Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells" (volume 7, issue 2 February 2008) is the first original publication of a preclinical studies in silencing of the Wnt-1 gene. Our results significantly indicate that anti-Wnt-1 siRNA inhibits Wnt-1 signaling, inducing apoptosis in human breast cancer cells and thus may serve as a potential anticancer drug.
http://www.landesbioscience.com/journals/cbt/article/5300
11-10-2007 Celon research at Cancer Therapeutics Conference.Celon Pharma Ltd presented results of preclinical studies using siRNA in EGFR pathway inhibition. Data were shown during Cancer Therapeutics: The Road Ahead Conference on Capri from October 8th to 10th in 2007.
Epidermal growth factor receptor family members (ErbBs) are currently major targets of anticancer strategies and identifying the contribution of ErbBs to tumorigenesis is crucial for development of anti-ErbB therapies. Overexpression of EGFR may serve as a prognostic marker with respect to survival in advance breast cancer and recurrence in operable breast tumors. The downregulation of ErbBs members by RNA interference, especially in breast cancer offers a new mode for high effective and selective inhibition of specific gene expression.
03-07-2007 Celon Pharma Ltd. goes to in vivo experiments.Celon Pharma is planning to start first in vivo experiments using siRNA as an anticancer drug this year.
Planned in this project experiments are continuation of earlier in vitro screening tests, which purposing the preliminary estimation of the siRNA application in inhibition of tumor specific genes expression. The most interesting results were obtained for genes involved in uncontrolled proliferation, where we observed 70-90% inhibition of expression in comparison to negative control (scrambled siRNA). Also, we observed that silencing of target gene induced apoptosis at the level of 60-75%, and these results are similar to docetaxel which is commonly used in cancer therapy.
03-07-2007 Meet us at ECCO 14.Celon Pharma Ltd will present results of preclinical studies with new innovative drug based on RNA interference technology. Data will be shown during 14th European Cancer Conference in Barcelona from September 23rd to 27th in 2007.
Utilization of phenomenon of interference is innovative manner of interaction on molecular targets RNA, that makes it possible selective effecting to oncogenes and incrementation of tumor. This project is focused on specific approach for tumor therapy, we brake process at the level of transcription of gene involved in tumorgenesis. Such is directed consistent with world trends of searches approach and development of tumor medicine. Celon Pharma is doing currently a research above the prototype of the anticancer drug based on the siRNA technology.
Celon Pharma Sp. z o.o.
ul. Ogrodowa 2A
05-092 Łomianki / Kiełpin
ul. Ogrodowa 2A
05-092 Łomianki / Kiełpin
Celon Pharma © 2007 All Rights Reserved.
Designed by GREGMAR